Inhibrx Biosciences, Inc.
INBX
$14.17
$0.171.21%
| Weiss Ratings | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C+ | |||
| Rating Factors | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 8.09% | |||
| 30-Day Total Return | 9.76% | |||
| 60-Day Total Return | 0.57% | |||
| 90-Day Total Return | -9.80% | |||
| Year to Date Total Return | -7.08% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -26.12% | |||
| 52-Week Low % Change | 29.63% | |||
| Price | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $18.95 | |||
| 52-Week Low Price | $10.80 | |||
| 52-Week Low Price (Date) | Aug 12, 2024 | |||
| 52-Week High Price (Date) | Jun 05, 2024 | |||
| Valuation | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 202.66M | |||
| Enterprise Value | 58.11M | |||
| Price/Earnings (TTM) | 0.12 | |||
| Earnings Per Share (TTM) | 113.77 | |||
| Earnings Per Share Growth | -665.61% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1,085.27 | |||
| Price/Book (Q) | 1.52 | |||
| Enterprise Value/Revenue (TTM) | 290.57 | |||
| Price | $14.17 | |||
| Enterprise Value/EBITDA (TTM) | -0.22 | |||
| Enterprise Value/EBIT | -0.22 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 15.47M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 795 4220 | |||
| Address | 11025 North Torrey Pines Road La Jolla, CA 92037 | |||
| Website | inhibrx.com | |||
| Country | United States | |||
| Year Founded | 2024 | |||
| Profitability | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -131,693.50% | |||
| Profit Margin | 843,786.00% | |||
| Management Effectiveness | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -67.37% | |||
| Return on Equity | 1,905.92% | |||
| Income Statement | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 200.00K | |||
| Total Revenue (TTM) | 200.00K | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | -203.54M | |||
| EBITDA (TTM) | -261.10M | |||
| EBIT (TTM) | -263.39M | |||
| Net Income (TTM) | 1.69B | |||
| Net Income Avl. to Common (TTM) | 1.69B | |||
| Total Revenue Growth (Q YOY) | -93.88% | |||
| Earnings Growth (Q YOY) | 48.86% | |||
| EPS Diluted (TTM) | 113.77 | |||
| EPS Diluted Growth (Q YOY) | 55.25% | |||
| Balance Sheet | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 152.60M | |||
| Cash Per Share (Q) | $9.87 | |||
| Total Current Assets (Q) | 160.40M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 133.58M | |||
| Current Ratio (Q) | 3.938 | |||
| Book Value Per Share (Q) | $9.23 | |||
| Total Assets (Q) | 180.77M | |||
| Total Current Liabilities (Q) | 40.73M | |||
| Total Debt (Q) | 8.05M | |||
| Total Liabilities (Q) | 47.18M | |||
| Total Common Equity (Q) | 133.58M | |||
| Cash Flow | INBX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.60M | |||
| Cash from Financing (TTM) | 71.68M | |||
| Net Change in Cash (TTM) | -125.33M | |||
| Levered Free Cash Flow (TTM) | -99.82M | |||
| Cash from Operations (TTM) | -194.41M | |||
